PROVIDENCE – As the prevalence of Alzheimer’s disease grows, typical treatments for the neurodegenerative illness are rooted in an approach that’s about 90 years old.

And that treatment shows limited success against the devastating disease: Patients need to start these therapies in the very early stages to experience much of an effect, says neuroscience researcher Stevin A. Zorn, and even then, it’s “modest at best.” PBN Branded Content

Webster Bank Celebrates 90 Years

By Samuel Hanna, Executive Managing Director, Commercial Real Estate, Webster Bank This year, Webster Bank… Learn More

Zorn and his team at MindImmune Therapeutics, a University of Rhode Island spinout that will soon relocate to Providence, are taking a different approach to develop what they believe could be a

See Full Page